Compare BridgeBio Pharma Inc (BBIO) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs National Beverage Corp. — how do they compare? BridgeBio Pharma Inc trades at $84.9 (market cap $16.46B), while National Beverage Corp. trades at $30.89 (market cap $2.89B). The key difference: BridgeBio Pharma Inc is far larger — about 5.7× National Beverage Corp.'s market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| BBIO | FIZZ | |
|---|---|---|
Market Cap | $16.46B | $2.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $47.69 |
52-Week Low | $44.81 | $30.92 |
Enterprise Value | $18.02B | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
FIZZ (National Beverage Corp.) trades at $31.13, down 7.95% over 24 hours, with a bearish technical signal and recent earnings misses in three of the last four quarters. The company reported $1.2B revenue and $186.82M net income for 2025, with strong profitability margins but a negative net cash flow of $133.21M. A special dividend of $3.25 per share was declared, payable July 30, 2026, providing a near-term catalyst.
Outlook is mixed: strong fundamentals and dividend support value, but technical weakness and earnings misses signal caution. Risks include competitive pressures and consumer spending trends. Analyst consensus is cautious with 50% sell ratings. The stock presents a high-risk opportunity for dividend-focused investors amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
